Genmab grants employees restricted stock units and warrants

Genmab A/S said its Board of Directors approved an equity award for staff across the company and its subsidiaries, covering 13,794 restricted stock units and 13,331 warrants granted to employees of the Company and the Company's subsidiaries.¹

Each restricted stock unit carries no cost to the recipient and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.¹ The units were valued using the stock's price on the grant date, with the fair value of each restricted stock unit equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,268.¹

On timing, the restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant, subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors.¹

For the warrants, the exercise price is DKK 2,268 per warrant, and each warrant is awarded cost-free, entitling the holder to subscribe for one share of nominally DKK 1 upon payment of that exercise price.¹ Their calculated worth, by application of the Black-Scholes formula, comes to DKK 781.96 per warrant.¹

On the warrant schedule, the warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date.¹ The company noted the new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021.¹

Genmab described itself as an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.¹ The filing was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer, dated September 24, 2026.